GDMT for HFrEF typically includes evidence-based beta-blockers, angiotensin receptor neprilysin inhibitors (ARNIs), angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, mineralocorticoid receptor antagonists (MRA), and sodium-glucose cotransporter 2 inhibitors (SGLT2is), particularly in patients with obesity or T2DM [53]
doi: 10.1111/j.1365-2982.2009.01317.x 165 NishizawaMNakabayashiHUchidaKNakagawaANiijimaA
It is crucial to prioritize gut health and reduce exposure to toxins to support optimal detoxification and overall health
BPC-157 is sold for research purposes and is not approved by Health Canada or the FDA for human therapeutic use
Methods Male Wistar rats were used
Consequently, this leads to a loss of skin color in the affected regions, resulting in conspicuous pale spots ranging in size from a few millimeters to several centimeters (169)